Alagebrium: Phase IIb ongoing

ALT is enrolling 300 patients in the double-blind, placebo-controlled, U.S. Phase IIb SPECTRA trial. The patients will receive once daily alagebrium or placebo in combination with hydrochlorothiazide ...